Experimental cancer drug KD033 tested in early trial – but study halted
NCT ID NCT04242147
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tested an experimental drug called KD033 (SAR445710) in 45 adults with advanced or metastatic solid tumors. The main goal was to check safety and find the right dose, while also looking for any anti-cancer effects. The trial was terminated, so final results may be limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KD033 (SAR445710)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors.
What could go wrong
This is a very early Phase 1 trial, so safety and effectiveness are not yet proven. The study was terminated, meaning results may be limited or inconclusive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center - 333 Cottman Avenue - Site 141
Philadelphia, Pennsylvania, 19111, United States
-
Moffitt Cancer Center - Site 102
Tampa, Florida, 33612, United States
-
Roswell Park Cancer Institute - 665 Elm St - Site 062
Buffalo, New York, 14263, United States
-
UCLA Hematology/Oncology, 2020 Santa Monica Boulevard, Suite 600 - Site 042
Santa Monica, California, 90404, United States
-
University of Pittsburgh Medical Center - Hillman Cancer Center - 5150 Centre Avenue, Suite 301 - Site 132
Pittsburgh, Pennsylvania, 15232, United States